Search

Displaying results 4111 - 4120 of 10000 in total
  1. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    Zidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations. … [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  2. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    Prademagene zamikeracel is a sheet-based gene therapy comprising autologous cells isolated from skin punch biopsies of patients with mutations in the collagen type VII alpha 1 chain (COL7A1) gene. … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

    Synonyms: Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene, Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene
  3. Drug

    Hydrocortisone butyrate

    go.drugbank.com/drugs/DB14540
    ApprovedVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersSynonyms: H-17-B, 17-O-butyrylcortisol
  4. Drug

    Hydrocortisone probutate

    go.drugbank.com/drugs/DB14543
    ApprovedVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  5. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

    Synonyms: 2-(3-Butyramido-3,4,6-triiodophenylmethylene)butyric acid
  6. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Regulex D CapInternational brands: Scatron D
  7. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

    Synonyms: 2-(2-Diethylaminoethoxy)ethyl 2-ethyl-2-phenylbutyrate
  8. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative … It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

    Synonyms: (7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates
  10. Drug

    Oxyphenisatin acetate

    go.drugbank.com/drugs/DB14627
    ApprovedWithdrawn

    Oxyphenisatin acetate is the pro-drug of [oxyphenisatin] (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]

    Categories: Heterocyclic Compounds, 2-Ring